| |
| |
| Preface | |
| |
| |
| List of contributors | |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Vaccination: Past, Present and Future | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Vaccination: the past | |
| |
| |
| |
| Vaccination: the present | |
| |
| |
| |
| Vaccination: the future | |
| |
| |
| |
| Conclusion: the intangible value of vaccination | |
| |
| |
| References | |
| |
| |
| |
| Bioinformatics, DNA Microarrays and Proteomics in Vaccine Discovery: Competing or Complementary Technologies? | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| From genome sequence to vaccine discovery | |
| |
| |
| |
| A case study: the anti-meningococcus B vaccine | |
| |
| |
| |
| Comparison of the three approaches | |
| |
| |
| |
| Conclusions: a 'nomics' approach to vaccine discovery | |
| |
| |
| References | |
| |
| |
| |
| Technologies | |
| |
| |
| |
| Genome Sequencing and Analysis | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Genome sequencing | |
| |
| |
| |
| Genome analysis | |
| |
| |
| |
| Conclusion | |
| |
| |
| References | |
| |
| |
| |
| Understanding DNA Microarrays: Sources and Magnitudes of Variances in DNA Microarray Data Sets | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| DNA array formats | |
| |
| |
| |
| Data analysis methods | |
| |
| |
| |
| Sources and magnitudes of noise in DNA microarray experiments | |
| |
| |
| |
| Conclusions | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| |
| The Proteome, Anno Domini Two Zero Zero Three | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Some definitions | |
| |
| |
| |
| What methods exist to tackle the proteome complexity? | |
| |
| |
| |
| Quantitative proteomics | |
| |
| |
| |
| Pre-fractionation in proteome analysis | |
| |
| |
| |
| Multi-dimensional chromatography | |
| |
| |
| |
| Protein chip arrays | |
| |
| |
| |
| Imaging mass spectrometry | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| |
| Mass Spectrometry in Proteomics | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| MS technology | |
| |
| |
| |
| Principle of protein identification based on MS data | |
| |
| |
| |
| Proteomics workflows | |
| |
| |
| References | |
| |
| |
| |
| High Throughput Cloning, Expression and Purification Technologies | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Gene cloning | |
| |
| |
| |
| Protein expression | |
| |
| |
| |
| High-throughput protein purification | |
| |
| |
| |
| Validation of the pipeline and outlook | |
| |
| |
| |
| Conclusion | |
| |
| |
| References | |
| |
| |
| |
| Applications | |
| |
| |
| |
| Meningococcus B: from Genome to Vaccine | |
| |
| |
| |
| |
| Meningococcus, a major cause of bacterial meningitis | |
| |
| |
| |
| Group B meningococcus as an example of reverse vaccinology | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| |
| Vaccines Against Pathogenic Streptococci | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Comparative genomics of streptococci | |
| |
| |
| |
| A vaccine against group B streptococcus | |
| |
| |
| |
| A vaccine against group A streptococcus | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| |
| Identification of the 'Antigenome'--a Novel Tool for Design and Development of Subunit Vaccines Against Bacterial Pathogens | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Small DNA insert libraries--a tool to cover a pathogen's 'antigenome' | |
| |
| |
| |
| Proper display platforms | |
| |
| |
| |
| Selected human sera to provide imprints of pathogen encounters | |
| |
| |
| |
| Cognate antibodies reveal the 'antigenome' of a pathogen | |
| |
| |
| |
| How to retrieve from the 'antigenome' the candidate antigens for vaccine development | |
| |
| |
| |
| Summary and discussion | |
| |
| |
| References | |
| |
| |
| |
| Searching the Chlamydia Genomes for New Vaccine Candidates | |
| |
| |
| |
| |
| Old problems and new perspectives for chlamydial vaccines | |
| |
| |
| |
| Post-genomic approaches | |
| |
| |
| |
| Genomic screening results | |
| |
| |
| |
| Concluding considerations | |
| |
| |
| References | |
| |
| |
| |
| Proteomics and Anti-Chlamydia Vaccine Discovery | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Proteome analysis | |
| |
| |
| |
| Proteomics as a complement for genomics | |
| |
| |
| |
| Benefits that proteomics provide for vaccine development | |
| |
| |
| References | |
| |
| |
| |
| Proteome Analysis of Outer Membrane and Extracellular Proteins from Pseudomonas aeruginosa for Vaccine Discovery | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Membrane proteins in P. aeruginosa | |
| |
| |
| |
| Extracellular proteins in P. aeruginosa | |
| |
| |
| |
| Immunogenic proteins and vaccine discovery | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| Index | |